一个多状态平台模型用于瘤学临床试验中的时间到事件终点
Chih-Wei Lin1, Mario Nagase1, Sameer Doshi1
1Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
CPT: pharmacometrics & systems pharmacology
|October 20, 2023
概括
一个新的多状态模型准确地描述了瘤试验的终点,如瘤反应和整体存活率. 这个平台增强了临床试验设计和模拟,以改善药物开发.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 在瘤学试验中,时间到事件 (TTE) 终点至关重要.
- 现有的模型可能无法完全捕捉多个TTE终点及其相互依存的复杂性.
研究的目的:
- 开发一种灵活的多州平台模型,用于描述瘤学试验中的TTE终点.
- 准确地模拟发生在计划评估中的事件与持续发生的事件的危险.
主要方法:
- 用一个普通微分方程框架为一个多状态模型.
- 对于评估依赖事件 (瘤反应,进展性疾病,PFS审查器) 采用零碎的激增功能.
- 用于连续事件 (整体存活事件,OS审查器) 的零碎常数函数.
主要成果:
- 该模型准确地描述了瘤反应,进展性疾病,无进展生存率和计划评估附近的总生存率的观察到的危险激增.
- 与卡普兰-梅尔曲线有很好的一致性.
- 启用时间变量协变效应评估,以更好地了解疾病预后.
结论:
- 开发的多状态模型为分析瘤学中的多个TTE终点提供了一个强大的平台.
- 它有助于更好地估计基线危险和共变效应.
- 该模型可以通过模拟和对终点相关性的更深入理解来优化瘤学试验设计.
相关概念视频
Kaplan-Meier Approach
154
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
154
Assumptions of Survival Analysis
136
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
136
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Comparing the Survival Analysis of Two or More Groups
201
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
201
Introduction To Survival Analysis
251
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
251
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
74
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
74


